Detalhe da pesquisa
1.
HMGB1 released by mesothelial cells drives the development of asbestos-induced mesothelioma.
Proc Natl Acad Sci U S A
; 120(39): e2307999120, 2023 09 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37729199
2.
SOX10-Internal Tandem Duplications and PLAG1 or HMGA2 Fusions Segregate Eccrine-Type and Apocrine-Type Cutaneous Mixed Tumors.
Mod Pathol
; 37(3): 100430, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38266920
3.
Laparoscopic Colorectal Surgery with Anatomical Recognition with Artificial Intelligence Assistance for Nerves and Dissection Layers.
Ann Surg Oncol
; 31(3): 1690-1691, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38017127
4.
Nesprin1 deficiency is associated with poor prognosis of renal cell carcinoma and resistance to sunitinib treatment.
Oncology
; 2024 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38442705
5.
Apocrine carcinoma with marked sebocyte-like cytological features: A report of two cases.
J Cutan Pathol
; 51(2): 92-98, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37743579
6.
Comprehensive genomic profiling testing in Japanese castration-resistant prostate cancer patients: results of a single-center retrospective cohort study.
Jpn J Clin Oncol
; 54(2): 175-181, 2024 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37899139
7.
Loss of p16 Immunoexpression and Deletions of CDKN2A in the Progression of Extramammary Paget Disease: An Immunohistochemical and Genetic Study of 24 Invasive/Metastatic Cases.
Am J Dermatopathol
; 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38648029
8.
Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy.
Int J Urol
; 31(5): 526-533, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38240169
9.
BACH1 promotes clear cell renal cell carcinoma progression by upregulating oxidative stress-related tumorigenicity.
Cancer Sci
; 114(2): 436-448, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36178067
10.
A Japanese case of familial malignant melanoma with germline CDK4 variant incidentally diagnosed by cancer genome profiling.
J Hum Genet
; 68(5): 359-361, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36631500
11.
Recurrent PAK2 rearrangements in poroma with folliculo-sebaceous differentiation.
Histopathology
; 83(2): 310-319, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37199682
12.
Recurrent FOXK1::GRHL and GPS2::GRHL fusions in trichogerminoma.
J Pathol
; 257(1): 96-108, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35049062
13.
Preoperative fluorescent clip marking vs. India ink tattooing for tumor identification during colorectal surgery.
Int J Colorectal Dis
; 38(1): 204, 2023 Aug 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37530872
14.
Transcriptional repressor GATA binding 1 (TRPS1) immunoexpression in normal skin tissues and various cutaneous tumors.
J Cutan Pathol
; 50(11): 1006-1013, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37649299
15.
YAP1::MAML2 fusions in poromatosis: A report of two patients.
J Cutan Pathol
; 50(8): 695-701, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36723803
16.
Clinicopathologic and genetic characterization of invasive melanoma with BRAF V600K mutation: A study of 16 cases.
J Cutan Pathol
; 50(8): 739-747, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37226844
17.
Clinical outcomes of intraductal carcinoma or cribriform in radical prostatectomy specimens of men opting for active surveillance: data from the PRIAS-JAPAN study.
Int J Clin Oncol
; 28(2): 299-305, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36472710
18.
Asbestos induces mesothelial cell transformation via HMGB1-driven autophagy.
Proc Natl Acad Sci U S A
; 117(41): 25543-25552, 2020 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32999071
19.
Heterozygous germline BLM mutations increase susceptibility to asbestos and mesothelioma.
Proc Natl Acad Sci U S A
; 117(52): 33466-33473, 2020 12 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-33318203
20.
Impact of low and high body mass index on predicting therapeutic efficacy and prognosis in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors.
Int J Urol
; 30(3): 319-327, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36448526